These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 23612599)
1. Pentosidine determination in CSF: a potential biomarker of Alzheimer's disease? Monacelli F; Borghi R; Pacini D; Serrati C; Traverso N; Odetti P Clin Chem Lab Med; 2014 Jan; 52(1):117-20. PubMed ID: 23612599 [TBL] [Abstract][Full Text] [Related]
2. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467 [TBL] [Abstract][Full Text] [Related]
3. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Bär KJ; Franke S; Wenda B; Müller S; Kientsch-Engel R; Stein G; Sauer H Neurobiol Aging; 2003; 24(2):333-8. PubMed ID: 12498967 [TBL] [Abstract][Full Text] [Related]
4. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
8. Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer's Disease. Haddad M; Perrotte M; Landri S; Lepage A; Fülöp T; Ramassamy C J Alzheimers Dis; 2019; 69(3):751-762. PubMed ID: 31127773 [TBL] [Abstract][Full Text] [Related]
10. Amnestic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters. Monacelli F; Borghi R; Cammarata S; Nencioni A; Piccini A; Tabaton M; Odetti P J Alzheimers Dis; 2015; 45(1):89-95. PubMed ID: 25471189 [TBL] [Abstract][Full Text] [Related]
11. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805 [TBL] [Abstract][Full Text] [Related]
12. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139 [TBL] [Abstract][Full Text] [Related]
13. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
15. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis. Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998 [TBL] [Abstract][Full Text] [Related]
17. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]
18. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]